CD79A and ovarian carcinoma: As discussed in Part I, the authors identified IgA responses to BDNF and TSPAN7 autoantigens in ovarian cancer and found that recombinant BDNF and TSPAN7 IgA antibodies reduce xenograft tumor growth.